Literature DB >> 27671110

Antigen Targeting to Human HLA Class II Molecules Increases Efficacy of DNA Vaccination.

Gunnveig Grodeland1, Agnete Brunsvik Fredriksen2, Geir Åge Løset3,4, Elisabeth Vikse5, Lars Fugger6,7, Bjarne Bogen1,3.   

Abstract

It has been difficult to translate promising results from DNA vaccination in mice to larger animals and humans. Previously, DNA vaccines encoding proteins that target Ag to MHC class II (MHC-II) molecules on APCs have been shown to induce rapid, enhanced, and long-lasting Ag-specific Ab titers in mice. In this study, we describe two novel DNA vaccines that as proteins target HLA class II (HLA-II) molecules. These vaccine proteins cross-react with MHC-II molecules in several species of larger mammals. When tested in ferrets and pigs, a single DNA delivery with low doses of the HLA-II-targeted vaccines resulted in rapid and increased Ab responses. Importantly, painless intradermal jet delivery of DNA was as effective as delivery by needle injection followed by electroporation. As an indication that the vaccines could also be useful for human application, HLA-II-targeted vaccine proteins were found to increase human CD4+ T cell responses by a factor of ×103 in vitro. Thus, targeting of Ag to MHC-II molecules may represent an attractive strategy for increasing efficacy of DNA vaccines in larger animals and humans.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27671110      PMCID: PMC5073356          DOI: 10.4049/jimmunol.1600893

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity.

Authors:  A Biragyn; K Tani; M C Grimm; S Weeks; L W Kwak
Journal:  Nat Biotechnol       Date:  1999-03       Impact factor: 54.908

2.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

3.  Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens.

Authors:  H Holte; H K Blomhoff; K Beiske; S Funderud; P Torjesen; G Gaudernack; T Stokke; E B Smeland
Journal:  Eur J Immunol       Date:  1989-07       Impact factor: 5.532

4.  Modulation of immune responses with monoclonal antibodies. I. Effects on regional lymph node morphology and on anti-hapten responses to haptenized monoclonal antibodies.

Authors:  S Mjaaland; S Fossum
Journal:  Eur J Immunol       Date:  1990-07       Impact factor: 5.532

5.  Two populations of Ia-like molecules on a human B cell line.

Authors:  L A Lampson; R Levy
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

6.  Structural polymorphism of human DR antigens.

Authors:  J Silver; S Ferrone
Journal:  Nature       Date:  1979-05-31       Impact factor: 49.962

7.  Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates.

Authors:  Gro Tunheim; Keith M Thompson; Agnete B Fredriksen; Terje Espevik; Karoline W Schjetne; Bjarne Bogen
Journal:  Vaccine       Date:  2007-04-20       Impact factor: 3.641

Review 8.  Accelerating next-generation vaccine development for global disease prevention.

Authors:  Wayne C Koff; Dennis R Burton; Philip R Johnson; Bruce D Walker; Charles R King; Gary J Nabel; Rafi Ahmed; Maharaj K Bhan; Stanley A Plotkin
Journal:  Science       Date:  2013-05-31       Impact factor: 47.728

9.  Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro.

Authors:  G Baier; G Baier-Bitterlich; D J Looney; A Altman
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

10.  Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. I. Significant variation in repertoire expression between individual mice.

Authors:  L M Staudt; W Gerhard
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more
  16 in total

1.  Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer.

Authors:  Kaïdre Bendjama; Eric Quemeneur
Journal:  Hum Vaccin Immunother       Date:  2017-08-28       Impact factor: 3.452

2.  Simultaneous Targeting of Multiple Hemagglutinins to APCs for Induction of Broad Immunity against Influenza.

Authors:  Ane Marie Anderson; Marta Baranowska-Hustad; Ranveig Braathen; Gunnveig Grodeland; Bjarne Bogen
Journal:  J Immunol       Date:  2018-02-02       Impact factor: 5.422

3.  Dendritic Cells Targeting Lactobacillus plantarum Strain NC8 with a Surface-Displayed Single-Chain Variable Fragment of CD11c Induce an Antigen-Specific Protective Cellular Immune Response.

Authors:  Jing Liu; Guilian Yang; Haibin Huang; Chunwei Shi; Xing Gao; Wentao Yang; Zan Zhang; Yang Liu; Ke Xu; Jianzhong Wang; Yuanhuan Kang; Yanlong Jiang; Chunfeng Wang
Journal:  Infect Immun       Date:  2020-01-22       Impact factor: 3.441

4.  Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy.

Authors:  A Schlüter; M Horstmann; S Diaz-Cano; S Plöhn; K Stähr; S Mattheis; M Oeverhaus; S Lang; U Flögel; U Berchner-Pfannschmidt; A Eckstein; J P Banga
Journal:  Clin Exp Immunol       Date:  2017-11-17       Impact factor: 4.330

5.  A DNA Vaccine That Targets Hemagglutinin to Antigen-Presenting Cells Protects Mice against H7 Influenza.

Authors:  Tor Kristian Andersen; Fan Zhou; Rebecca Cox; Bjarne Bogen; Gunnveig Grødeland
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

6.  The anti-influenza M2e antibody response is promoted by XCR1 targeting in pig skin.

Authors:  Charlotte Deloizy; Even Fossum; Christophe Barnier-Quer; Céline Urien; Tiphany Chrun; Audrey Duval; Maelle Codjovi; Edwige Bouguyon; Pauline Maisonnasse; Pierre-Louis Hervé; Céline Barc; Olivier Boulesteix; Jérémy Pezant; Christophe Chevalier; Nicolas Collin; Marc Dalod; Bjarne Bogen; Nicolas Bertho; Isabelle Schwartz-Cornil
Journal:  Sci Rep       Date:  2017-08-09       Impact factor: 4.379

7.  A Rift Valley fever virus Gn ectodomain-based DNA vaccine induces a partial protection not improved by APC targeting.

Authors:  Tiphany Chrun; Sandra Lacôte; Céline Urien; Luc Jouneau; Céline Barc; Edwige Bouguyon; Vanessa Contreras; Audrey Ferrier-Rembert; Christophe N Peyrefitte; Nuria Busquets; Enric Vidal; Joan Pujols; Philippe Marianneau; Isabelle Schwartz-Cornil
Journal:  NPJ Vaccines       Date:  2018-04-20       Impact factor: 7.344

8.  A DNA Vaccine in Which the RSV-F Ectodomain Is Covalently Linked to the Burkholderia pseudomallei Antigens TssM and Hcp1 Augments the Humoral and Cytotoxic Response in Mice.

Authors:  Victor Solodushko; Vira Bitko; Robert Barrington; Brian Fouty
Journal:  Front Immunol       Date:  2019-10-11       Impact factor: 7.561

9.  A DNA Prime Immuno-Potentiates a Modified Live Vaccine against the Porcine Reproductive and Respiratory Syndrome Virus but Does Not Improve Heterologous Protection.

Authors:  Cindy Bernelin-Cottet; Céline Urien; Maxence Fretaud; Christelle Langevin; Ivan Trus; Luc Jouneau; Fany Blanc; Jean-Jacques Leplat; Céline Barc; Olivier Boulesteix; Mickaël Riou; Marilyn Dysart; Sophie Mahé; Elisabeth Studsrub; Hans Nauwynck; Nicolas Bertho; Olivier Bourry; Isabelle Schwartz-Cornil
Journal:  Viruses       Date:  2019-06-25       Impact factor: 5.048

Review 10.  A Review of DNA Vaccines Against Influenza.

Authors:  Leo Yi Yang Lee; Leonard Izzard; Aeron C Hurt
Journal:  Front Immunol       Date:  2018-07-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.